Drugs / HS-10516
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06553339 | Jul 2024 → Jul 2026 overdue | hereditary clear cell renal cell carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06049030 | Sep 2023 → Sep 2024 | clear cell renal carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07239596 | Jan 2026 → Dec 2030 expected | renal cell carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07097935 | Jul 2025 → Jul 2027 expected | clear cell renal carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10516 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07097935 ↗ |
| Action | Inhibit | “HIF-2α inhibitor” NCT06049030 ↗ |
| Route | Oral | “administrated orally once daily” NCT06049030 ↗ |